A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER)

Sponsor
Hoffmann-La Roche
Study ID
NCT01378962
Phase
PHASE2
Status
Completed

Conditions

  • Non-Squamous Non-Small Cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • erlotinib — DRUG
    150 mg orally once a day for 12 months

Study Details

This single-arm, open-label study evaluated the efficacy and safety of Tarceva (erlotinib) in participants with locally advanced or metastatic non-small cell lung cancer. Participants received daily oral doses of 150 mg Tarceva. The anticipated time on study treatment was 12 months.

Key Dates

First listed
Jun 23, 2011
Start date
Mar 31, 2011
Status verified
Dec 2017
Primary completion
Jun 30, 2013
Completion
Jan 31, 2017

Study Design

Enrollment
50 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Single Arm

Primary Outcome Measure

Percentage of Participants With Disease Progression or Death at 12 Months After Baseline [ Time Frame: 12 months ]

Related Studies